The Institute of Biophysics and Cell Engineering offers consumers services for the treatment of gingival recession and chronic periodontitis using autologous mesemchial stem cells, including services using these methods for adult patients In accordance with the medical license under an outsourcing agreement, and is looking for partners interested in a distribution services agreement.

The use of a suspension of biomedical cell product (BMCP) based on autologous mesenchymal stem cells of adipose tissue in a 7% collagen gel increases the effectiveness of traditional treatment of gingival recession and can significantly improve the quality of life of patients. Treatment of chronic periodontitis using BMCP based on autologous mesenchymal stem cells of adipose tissue induced to differentiate in the osteogenic direction provides more effective treatment of moderate to severe periodontal diseases. The treatment uses registered BMCP "Mesenchymal stem cells" (TU BY 100217351.004-2014, amendment No. 1) and "Mesenchymal stem cells induced to differentiate in the osteogenic direction" (TU BY 100217351.014-2022). Album of promising developments of the NAS of Belarus organizations for the real sector of the economy298

Developers: State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus", Educational Institution "Belarusian State Medical University", State Educational Institution "Belarusian Medical Academy of Postgraduate Education".

Improved treatment results for gum recession and chronic periodontitis (K05 and K06 according to ICD-10).

Scope - medicine, dentistry.

Product consumers - healthcare organizations providing medical care to patients in outpatient, inpatient, and day hospital settings.

More information about paid services for the population can be found on the Institute's website here.

Information is posted in Album of promising developments of the NAS of Belarus organizations for the real sector of the economy (2023), , стр. 298-299. (in Russian)

Treatment of gum recession and chronic periodontitis using autologous mesenchymal stem cells is carried out only in the Department of Cell Therapy of the State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus".

Medical services associated with cell therapy are provided to patients of the Republic of Belarus and foreign citizens.

As a result of the studies, a decrease in gum recession in all examined teeth of patients was established by 61.5%, and the volume of mucosal tissue increased by 2.6 times. Healing and proliferation of the mucosa, complete filling of interdental spaces were observed. The method of treating periodontal diseases of moderate to severe severity was tested on 10 patients. The effectiveness of cell therapy with an interval after cell transplantation of 6 months was shown: a decrease in the depth of bone pockets by 53.3%.

The developed treatment method showed good tolerability and safety of use for the patient. Side effects are rare and do not pose a health hazard. The method is environmentally safe.

The Department of Cell Therapy of the State Scientific Institution “Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus” provides medical services to the population on a paid basis.

1. Instructions for use "Method for treating gingival recession using a mixture of autologous adipose tissue-derived mesenchymal stem cells with 7% collagen gel", reg. No. 048-0518 dated 01.06.2018.(in Russian)
2. Instructions for use "Method for treating chronic periodontitis using adipose tissue-derived mesenchymal stem cells induced to differentiate in the osteogenic direction", reg. No. 163-1220 dated 29.12.2020. (in Russian)

State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus" is a leading scientific center in the field of biophysics.

Directions of fundamental and applied scientific research of the Institute.

In the field of medical biotechnology:
- genetic engineering - development of innovative biomedical cell products based on genetically modified cells;
- immunology and allergology - development of new methods of treatment and diagnosis of allergic diseases and immune dysfunctions;
- innovative vaccines - development of prototypes of domestic DNA and RNA vaccines for the prevention of viral diseases;
- new approaches to diagnostics - development of new technologies for early diagnosis of diseases and methods of personalized medicine aimed at improving the quality of human life;
- genome editing - somatic, induced pluripotent stem cells, which will allow treating diseases, including orphan, genetic;
- synthetic morphogenesis - including tissue and organ engineering.

In the field of bioinformatics technologies:
- structure-based design of new-generation drugs, development of innovative targeted antitumor and antiviral drugs using structural bioinformatics methods;
- synthesis of targeted drugs and their testing in vitro.

In the field of nanotheranostics and personalized nanomedicine:
- development of means of targeted delivery of new-generation therapeutic drugs using nanomaterials;
- development of biological nanochips for disease diagnostics;
- study of broad-spectrum biocompatible nanomaterials for the creation of biomedical cellular products, artificial organs, fundamentally new materials with antimicrobial, antiviral and anti-inflammatory activity.

Activities of the Center for Experimental and Applied Virology:
- culturing viruses, developing new methods for culturing human viruses to create diagnostic tools, medical prevention and treatment of viral diseases;
- creation of vaccine prototypes - against influenza (inactivated and recombinant), against African swine fever (vector), against pulmonary tuberculosis (therapeutic based on donor dendritic cells), innovative drugs against influenza.

Over the past years, the Institute has implemented a number of international contracts and agreements within the Framework Programs of the European Union, as well as with leading scientific centers, foundations, and societies.

Consumers interested in purchasing autologous mesemchial stem cell-based treatments for gingival recession and chronic periodontitis, including adult patient services using these methods in accordance with the medical license under an outsourcing agreement.

Partners interested in purchasing autologous mesemchial stem cell-based treatments for gingival recession and chronic periodontitis, including adult patient services using these methods in accordance with the medical license under a distribution services agreement.